News

14.03.2019
Octapharma Group reports strong results for 2018

Reporting revenue of €1.8 billion and operating income of €346 millionGroup sales increased 4.5% com...

26.11.2018
Octapharma receives Swissmedic approval for fibryga® to treat congenital and acquired fibrinogen deficiencies

Lachen, Switzerland – 26 November 2018 – Octapharma today announced that the Swiss Agency for Therap...

Since its establishment over 30 years ago, Octapharma has grown into a truly global company providing life enhancing therapies to patients in over 100 countries. To find your local Octapharma office, access our global locations map

“As a world-wide provider of human proteins as treatments in immunotherapy, haematology, and intensive care and emergency medicine, Octapharma is constantly investing in the renovation and modernisation of our plants.„

Wolfgang Marguerre
Chairman of the Board